Tiziana Life Sciences announces agreement with STC Biologics
NEW YORK: Tiziana Life Sciences plc, a clinical stage biotechnology company, announced the execution of an agreement with STC Biologics Inc. for GMP manufacturing of TZLS-501, an anti-IL-6 receptor monoclonal antibody (mAb) acquired from Novimmune in 2017, currently in agreement…